Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The company launched a Phase 2b trial with the ambition of registering AOD-9604 as an obesity drug
Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
Inhibition of lipogenesis AOD-9604 not only breaks down existing fat, but also brakes the formation of new fat
Noonan syndrome A dysmorphic syndrome associated with phenotypical congenital heart defects and short stature (OMIM 615355)
US$ 25.17
US$ 29.17
US$ 20.21
US$ 28.88
US$ 28.21
US$ 27.09
US$ 26.26
